Corton Capital Inc. Intellia Therapeutics, Inc. Transaction History

Corton Capital Inc.

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$20.02 - $27.22 $216,476 - $294,329	10,813 Added 123.97%	19,535 $437,000
Q1 2024 May 15, 2024	SELL	$23.82 - $32.8 $34,872 - $48,019	-1,464 Reduced 14.37%	8,722 $239,000
Q4 2023 Feb 14, 2024	SELL	$23.16 - $32.34 $90,370 - $126,190	-3,902 Reduced 27.7%	10,186 $310,000
Q3 2023 Nov 14, 2023	BUY	$31.62 - $45.78 $213,118 - $308,557	6,740 Added 91.73%	14,088 $445,000
Q2 2023 Aug 14, 2023	BUY	$34.58 - $46.03 $25,623 - $34,108	741 Added 11.22%	7,348 $299,000
Q1 2023 May 15, 2023	BUY	$33.3 - $44.82 $220,013 - $296,125	6,607 New	6,607 $246,000

313

91.5M

442K

880K

Ticker NTLA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,011,800
Market Cap $929M
Description
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...

Get notified when there are updates to the investment portfolio of Corton Capital Inc., based on Form 13F filings with the SEC.

Stay updated on Corton Capital Inc. with notifications on news.